aTyr Pharma, Inc.

NASDAQ:ATYR

Biotechnology

Healthcare
$0.53 +14.23%

+$0.07 today

Market cap
$52.13M
Beta
0.54
P/E (TTM)
-0.7
EPS (TTM)
-$0.71
52W Low $0.40High $7.29

Volume 1.02M

Average 2.29M

ATYR Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

aTyr Pharma, Inc.NASDAQ: ATYR

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$394K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$22.33M.

Context

  • Gross profit amounted to 717.4% of revenue in FY2025, up 617.4 pp from a year earlier.
  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$394K or moves back toward the trailing-twelve-month quarterly average of -$5.58M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$394K— QoQ
Last fiscal yearDec 2025
-$1.36M-680.0% YoY
LTMMar 2026
-$22.33M-82.6% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-680.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(1.36M) USD
Year-over-year change
-680.0%

Gross Profit vs competitors

How ATYR compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -82.6% is the lowest of 6, against a peer median of +31.8%.
  • Gross profit amounts to 11754.7% of revenue for ATYR, versus a peer median of 76.2%.
ATYR Competitors
Gross Profit for ATYR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DTILPrecision BioSciences, Inc.LTM Mar 2026$43.7M USD-14.6%+7.9%97.0%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$11.07M CAD+26.1%+7.2%60.3%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$3M USD+337.0%—76.2%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$228K USD+137.1%——
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 USD———
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$150K USD+31.8%——
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026-$211K USD———
ATYRaTyr Pharma, Inc.LTM Mar 2026-$22.33M USD-82.6%—11754.7%
Peer median (excluding ATYR) —+31.8%+7.6%76.2%

Competitors are the stored peer set for ATYR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue010.39M353K235K190K
Cost of Revenue1.3M1.7M001.55M
Gross Profit(1.3M)8.69M353K235K(1.36M)
Gross Margin—83.7%100.0%100.0%-717.4%
Research & Development23.26M42.81M42.29M54.37M60.22M
Selling, General & Admin10.75M12.29M12.98M13.78M17.6M
Operating Expenses32.71M55.1M55.27M68.15M76.26M
Depreciation & Amortization1.3M1.7M2.74M1.54M1.55M
EBITDA(32.47M)(43.65M)(47.66M)(62.48M)(72.57M)
EBITDA Margin—-420.3%-13500.3%-26588.1%-38192.1%
Operating Income(34.02M)(46.4M)(54.92M)(67.91M)(77.63M)
Operating Margin—-446.8%-15557.8%-28899.6%-40856.3%
Interest Income00000
Interest Expense00000
Other Income / Expenses238K1.06M4.52M3.89M3.51M
Income Before Tax(33.78M)(45.34M)(50.4M)(64.02M)(74.12M)
Pre-Tax Margin—-436.6%-14276.8%-27243.4%-39009.5%
Income Tax Expense00000
Net Income(33.77M)(45.34M)(50.39M)(64.02M)(74.12M)
Net Margin—-436.5%-14274.5%-27243.8%-39009.5%
EPS (Basic)(1.77)(1.60)(0.94)(0.86)(0.80)
EPS (Diluted)(1.77)(1.60)(0.94)(0.86)(0.80)
Weighted Avg Shares19.08M28.42M53.61M74.26M92.99M
Weighted Avg Shares (Diluted)19.08M28.42M53.61M74.26M92.99M

aTyr Pharma, Inc.

NASDAQ:ATYR

Intrinsic Alpha fair value

Locked

Current Price

$0.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.